Last Updated: May 12, 2026

Claims for Patent: 8,114,836

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,114,836

Title:	Long-acting veterinary polypeptides and methods of producing and administering same
Abstract:	A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also disclosed.
Inventor(s):	Fares; Fuad (Hourfish Village, IL), Fima; Udi Eyal (Beer-Sheva, IL)
Assignee:	Prolor Biotech Ltd. (Nes Ziona, IL)
Application Number:	12/401,755
Patent Claims:	1. A polypeptide consisting of a non-human growth hormone polypeptide, one chorionic gonadotrophin carboxy terminal peptide attached to the amino terminus of said non-human growth hormone polypeptide, and two chorionic gonadotrophin carboxy terminal peptides attached to the carboxy terminus of said non-human growth hormone polypeptide. 2. The polypeptide of claim 1, wherein the sequence of at least a single chorionic gonadotrophin carboxy terminal peptide consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 17 and SEQ ID NO: 18. 3. The polypeptide of claim 1, wherein at least a single chorionic gonadotrophin carboxy terminal peptide is truncated. 4. A composition comprising the polypeptide of claim 1 and a pharmaceutically acceptable carrier. 5. A polypeptide consisting of a non-human growth hormone polypeptide, one chorionic gonadotrophin carboxy terminal peptide attached to the amino terminus of said non-human growth hormone polypeptide, two chorionic gonadotrophin carboxy terminal peptides attached to the carboxy terminus of said non-human growth hormone polypeptide, and a signal peptide attached to the amino terminus of said one chorionic gonadotrophin carboxy terminal peptide. 6. The polypeptide of claim 5, wherein the sequence of said signal peptide is as set forth in SEQ ID NO: 19. 7. The polypeptide of claim 5, wherein the sequence of at least a single chorionic gonadotropin carboxy terminal peptide consists of an amino acid sequence selected from the group consisting of SEQ ID NO: 17 and SEQ ID NO: 18. 8. The polypeptide of claim 5, wherein at least a single chorionic gonadotrophin carboxy terminal peptide is truncated. 9. A composition comprising the polypeptide of claim 5 and a pharmaceutically acceptable carrier. 10. A method of extending the biological half life of a non-human growth hormone polypeptide, comprising the step of attaching one chorionic gonadotrophin carboxy terminal peptide to the amino terminus of said non-human growth hormone polypeptide and two chorionic gonadotrophin carboxy terminal peptides to the carboxy terminus of said non-human growth hormone polypeptide, thereby extending the biological half life of a non-human growth hormone polypeptide. 11. The method of claim 10, wherein the sequence of at least a single chorionic gonadotrophin carboxy tei iiiinal peptide consists of an amino acid sequence selected from the group consisting of: SEQ ID NO: 17 and SEQ ID NO: 18. 12. The method of claim 10, wherein at least a single chorionic gonadotrophin carboxy terminal peptide is truncated. 13. A method of extending the biological half life of a non-human growth hormone polypeptide, comprising the step of attaching one chorionic gonadotrophin carboxy terminal peptide to the amino terminus of said non-human growth hormone polypeptide and two chorionic gonadotrophin carboxy terminal peptides to the carboxy terminus of said non-human growth hormone polypeptide, and a signal peptide attached to the amino terminus of said one chorionic gonadotrophin carboxy terminal peptide, thereby extending the biological half life of a non-human growth hormone polypeptide. 14. The method of claim 13, wherein the sequence of at least a single chorionic gonadotrophin carboxy terminal peptide consists of an amino acid sequence selected from the group consisting of: SEQ ID NO: 17 and SEQ ID NO: 18. 15. The method of claim 13, wherein at least a single chorionic gonadotrophin carboxy terminal peptide is truncated. 16. The method of claim 13, wherein the sequence of said signal peptide is as set forth in SEQ ID NO: 19.

Details for Patent 8,114,836

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	January 15, 1974	⤷ Start Trial	2029-03-11
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	December 27, 1984	⤷ Start Trial	2029-03-11
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 15, 1985	⤷ Start Trial	2029-03-11
Ferring Pharmaceuticals Inc.	NOVAREL	chorionic gonadotropin	For Injection	017016	February 16, 1990	⤷ Start Trial	2029-03-11
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.